Literature DB >> 31586650

Phenotypic variability in two patients with tumor necrosis factor receptor associated periodic fever syndrome emphasizes a rare manifestation: Immunoglobulin A nephropathy.

Sibel Balci1, Rabia Miray Kisla Ekinci2, Engin Melek3, Bahriye Atmis4, Atıl Bisgin5, Mustafa Yilmaz6.   

Abstract

Tumor necrosis factor receptor associated periodic fever syndrome (TRAPS) is caused by heterozygote mutations in TNFRSF1A, characterized by recurrent inflammatory attacks. In this report, we described two patients with different heterozygote mutations in TNFRSF1A. Patient 1, a 15-year-old male, had suffered from recurrent fever attacks accompanied by abdominal pain, eye manifestations, and myalgia with increased acute phase reactants since the age of 6-month. He had been unsuccessfully treated with colchicine for having familial Mediterranean fever without an identifiable MEFV mutation since the age of 4-year. At the age of 15 years, he was diagnosed with immunoglobulin (Ig) A nephropathy due to massive proteinuria and renal biopsy findings. Next generation sequencing revealed NM_001065.3: c.236C>T; p. (Thr79Met); T50M heterozygote mutation in TNFRFS1A. He was treated with methylprednisolone and cyclosporine for IgA nephropathy, thereafter with canakinumab for TRAPS. Patient 2, a 17-year-old female, had recurrent arthritis attacks accompanied by increased acute phase reactants for the last two months. She had neither fever attacks nor rashes or myalgia. Her physical examination was normal between attacks. Magnetic resonance imaging of both knees and ankles showed no signs of chronic arthritis. MEFV analyzes showed no mutation. Next generation sequencing revealed NM_001065.3: c.362G>A; p.(Arg121Gln); R92Q heterozygote mutation in TNFRFS1A. Arthritis attacks were treated successfully with ibuprofen thereafter. In conclusion, we wish to emphasize the diversity of the clinical manifestations between these two patients with distinct sequence variants in TNFRSF1A. Moreover, we presented a rare manifestation of TRAPS, IgA nephropathy.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  IgA nephropathy; R92Q; Recurrent arthritis; T50M; TRAPS; Tumor necrosis factor receptor associated periodic syndrome

Year:  2019        PMID: 31586650     DOI: 10.1016/j.ejmg.2019.103780

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  2 in total

1.  Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network.

Authors:  Antonio Vitale; Jurgen Sota; Laura Obici; Nicola Ricco; Maria Cristina Maggio; Marco Cattalini; Piero Ruscitti; Francesco Caso; Raffaele Manna; Ombretta Viapiana; Valeria Caggiano; Giacomo Emmi; Antonella Insalaco; Davide Montin; Francesco Licciardi; Alessandra Soriano; Lorenzo Dagna; Carlo Salvarani; Vittoria Lamacchia; José Hernández-Rodríguez; Roberto Giacomelli; Bruno Frediani; Alessandra Renieri; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2020-05-27       Impact factor: 4.711

2.  Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.

Authors:  Carla Gaggiano; Donato Rigante; José Hernández-Rodríguez; Antonio Vitale; Maria Tarsia; Alessandra Soriano; Giuseppe Lopalco; Florenzo Iannone; Masen Abdel Jaber; Roberto Giacomelli; Ewa Wiȩsik-Szewczyk; Marco Cattalini; Micol Frassi; Matteo Piga; Gaafar Ragab; Jurgen Sota; Fiammetta Zunica; Alberto Floris; Vito Sabato; Mohamed Tharwat Hegazy; Olga Araújo; Laura Pelegrín; Alessandra Fabbiani; Alessandra Renieri; Salvatore Grosso; Claudia Fabiani; Bruno Frediani; Luca Cantarini
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-09-09       Impact factor: 5.346

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.